Gain Therapeutics, Inc. (GANX) Debt-to-equity % [USD] 2022 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Gain Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from 2022 to 2024.
Gain Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 65.3 %, a 149% increase year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	65.3	+39.1	+149%	Mar 31, 2024
Q4 2023	56.7	+35.2	+164%	Dec 31, 2023
Q3 2023	48.3	+30.7	+175%	Sep 30, 2023
Q2 2023	35.8			Jun 30, 2023
Q1 2023	26.2			Mar 31, 2023
Q4 2022	21.4			Dec 31, 2022
Q3 2022	17.6			Sep 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.